Psoriasis is one of the commonest chronic inflammatory disorders. Its cause is unknown, but
a wealth of studies indicate that the disease results from a complex and dynamic interplay …

Objectives While off-label dosing of biologic treatments may be necessary in selected
psoriasis patients, no systematic review exists to date that synthesizes the efficacy and …

Objective To investigate the therapeutic effect of CBD-ointment administered on severe skin
chronic diseases and/or on their outcome scars. Methods A spontaneous, anecdotal …

Objective To describe the use of systemic therapy for psoriasis (biologic and nonbiologic
[classic] drugs) in patients not adequately represented in randomized controlled trials …

Biological therapy has revolutionized moderate to severe psoriasis treatment. However,
despite being more effective than conventional systemic treatments, some patients do not …

Background Head‐to‐head randomized studies comparing ixekizumab and secukinumab in
the treatment of psoriasis are not available. Objectives To assess efficacy and quality of life …

Purpose Advances in the treatment of moderate-to-severe plaque psoriasis, including new
biological agents and related drugs, are reviewed. Summary Most patients with psoriasis …

Guselkumab, a subcutaneously administered fully human IgG1 monoclonal antibody that
selectively inhibits the p19 subunit of interleukin 23, is approved in both the USA and the EU …

Nanocarriers, and especially nanostructured lipid carriers (NLC), represent one of the most
effective systems for topical drug administration. NLCs are biodegradable, biocompatible …

Background Little is known about the adverse events (AE s) that lead to suspension of
systemic treatments for psoriasis in clinical practice. Objective The study aimed to …